Skip to content. | Skip to navigation

Personal tools

Sections

Tutelles

logo Inserm      logo cnrslogo ENSL       logo ucb1

You are here: Home / Teams / Paul S - GIMAP / Publications

Publications

Scientific articles

 

Top 20% best publications with team member as leader

  1. Gutjahr A, Papagno L, Nicoli F, Kanuma T, Kuse N, Cabral-Piccin MP, Rochereau N, Gostick E, Lioux T, Perouzel E, Price DA, Takiguchi M, Verrier B, Yamamoto T, Paul S & Appay V (equal contribution). The STING ligand cGAMP potentiates the efficacy of vaccine-induced CD8+ T cells. JCI Insight. 2019; 4;4(7). eCollection 2019. IF=13.25
  • Results identify particular isoforms of cGAMP (cyclic guanosine monophosphate-adenosine monophosphate) as effective adjuvants that may find utility in the development of novel immunotherapies and vaccines.
  1. Jullien P, Laurent B, Claisse G, Masson I, Dinic M, Thibaudin D, Berthoux F, Alamartine E, Mariat C, Maillard N. Deletion variants of CFHR1 and CFHR3 associate with mesangial immune deposits but not with progression of IgA nephropathy. J Am Soc Nephrol. 2018;29:661-669. IF=8.66
  • Demonstration the CFHR3,1Δ genotype did not associate with progression toward CKD stages 3 and 5 in our white population of patients with IgA nephropathy, although it did associate with a reduced level of glomerular immune deposits.
  1. Gutjahr A, Papagno L, Nicoli F, Vernejoul F, Lioux T, Tiraby G, Perouzel E, Appay V, Verrier B,  Paul S. Cutting Edge: A Dual TLR2 and TLR7 Ligand Induces Highly Potent Humoral and Cell-Mediated Immune Responses. J Immunol. 2017 Jun 1;198(11):4205-4209  IF=5.8
  • TLR agonists are currently being developed and tested as adjuvants in various formulations to optimize the immunogenicity and efficacy of vaccines. The aim of this study was to evaluate the immunostimulatory properties of a novel compound incorporating covalently linked moieties designed to stimulate both TLR2 and TLR7. This dual TLR2/TLR7 agonist induced the maturation of dendritic cells and primed substantial populations of cytolytic and highly polyfunctional effector CD8+ T cells in vitro, and safely potentiated the immunogenic properties of a nanoparticulate Ag in vivo, eliciting humoral responses with a balanced TH1/TH2 profile in mice. Collectively, these data reveal the potential utility of chimeric adjuvants with synergistic activities mediated via TLRs.
  1. Benjelloun F, Oruc Z, Thielens N, Verrier B, Champier G, Vincent N, Rochereau N, Girard A, Jospin F, Chanut B, Genin C, Cogné M, Paul S. First Membrane Proximal External Region-Specific Anti-HIV1 Broadly Neutralizing Monoclonal IgA1 Presenting Short CDRH3 and Low Somatic Mutations. J Immunol. 2016; 1;197(5):1979-88. IF=5.8
  • In vivo generation of gp41-specific IgA1 that could be of interest in prophylactic treatment to block HIV-1 penetration in mucosa or in chronically infected patients in combination with antiretroviral therapy to reduce viral load and reservoir.
  1. Rochereau N, Pavot V, Verrier B, Jospin F, Ensinas A, Genin C, Corthésy B, Paul S. Delivery of antigen to nasal-associated lymphoid tissue microfold cells through secretory IgA targeting local dendritic cells confers protective immunity. J Allergy Clin Immunol. 2016;137:214-222. IF=13.1
  • This study represents the first example that underscores the remarkable potential of SIgA to serve as a carrier for a protein antigen in a mucosal vaccine approach targeting the nasal environment.
  1. Pavot V, Climent N, Rochereau N, Garcia F, Genin C, Tiraby G, Vernejoul F, Perouzel E, Lioux T, Verrier B, Paul S. Directing vaccine immune responses to mucosa by nanosized particulate carriers encapsulating NOD ligands. Biomaterials. 2016;75:327-339. IF=8.40
  • Results provide a rational approach for combining nanosized particulate carriers and encapsulated NOD receptor ligands as potent synergistic tools for induction of specific mucosal immunity.
  1. Pillet S, Williet N, Pouvaret A, Del Tedesco E, Saint-Sardos P, Pozzetto B, Roblin X. Distribution of Cytomegalovirus DNA Load in the Inflamed Colon of Ulcerative Colitis Patients. Am J Gastroenterol. 2016;111:439-41. IF=10.2
  • The measure of CMV DNA load is intended to orientate the immunosuppressive treatment of ulcerative colitis. The present observations plead for the systematic sampling of two biopsies for each flare-up episode. Depending on economic considerations and care organization, it is possible to either test a single biopsy with the ability, in case of discrepancy between the viral result and the clinical evolution, to analyze the second fragment or, as done in our center, test the two fragments simultaneously and consider the highest value of CMV DNA load as the predictive one for therapeutic management.
  1. Pavot V, Rochereau N, Rességuier J, Gutjahr A, Genin C, Tiraby G, Perouzel E, Lioux T, Vernejoul F, Verrier B, Paul S. Cutting edge: New chimeric NOD2/TLR2 adjuvant drastically increases vaccine immunogenicity. J Immunol. 2014; 15;193(12):5781-5. IF=5.8
  • Findings point out the potential utility of chimeric molecules TLR/NOD as adjuvants for vaccines to induce systemic and mucosal immune responses.

 

Other scientific articles (lead position)

 

  1. Girard A, Rallón N, Benito JM, Jospin F, Rodriguez C, Chanut B, Benjelloun F, Del Romero J, Verrier B, Lucht F, Pin JJ, Genin C, Biasin M, Clerici M, Paul S. A high mucosal blocking score is associated with HIV protection. AIDS. 2019 ; 1;33(3):411-423. IF=4.91
  2. Keita A, Sereme Y, Pillet S, Coulibaly S, Diallo F, Pozzetto B, Thiero TA, Bourlet T. Impact of HIV-1 primary drug resistance on the efficacy of a first-line antiretroviral regimen in the blood of newly diagnosed individuals in Bamako, Mali. J Antimicrob Chemother. 2019 Jan 1;74(1):165-171. IF=5.2
  3. Jullien P, Laurent B, Berthoux F, Masson I, Dinic M, Claisse G, Thibaudin D, Mariat C, Alamartine E, Maillard N. Repeat renal biopsy improves the Oxford classification-based prediction of immunoglobulin A nephropathy outcome. Nephrol Dial Transplant. 2018 (in press). IF=4.6
  4. Rigaill J, Morgene MF, Gavid M, Lelonge Y, He Z, Carricajo A, Grattard F, Pozzetto B, Berthelot P, Botelho-Nevers E, Verhoeven PO. Intracellular activity of antimicrobial compounds used for Staphylococcus aureus nasal decolonization. J Antimicrob Chemother. 2018;73:3044-3048. IF=5.2
  5. Morgene MF, Maurin C, Pillet S, Berthelot P, Morfin F, Pozzetto B, Botelho-Nevers E, Verhoeven PO. HaCaT epithelial cells as an innovative novel model of rhinovirus infection and impact of clarithromycin treatment on infection kinetics. Virology. 2018;523:27-34. IF=3.37
  • Description of an original model of epithelial cell infection by rhinovirus could be useful to study chronic viral infection and bacterium-virus interactions at the cell level. These results also suggest that clarithromycin may be evaluated for treating in vivo infections associating rhinovirus to a susceptible bacterium.
  1. Morgene MF, Botelho-Nevers E, Grattard F, Pillet S, Berthelot P, Pozzetto B, Verhoeven PO. Staphylococcus aureus colonization and non-influenza respiratory viruses: Interactions and synergism mechanisms.  Virulence. 2018; 9:1354-1363.
  2. Terrasse R, Memmi M, Palle S, Heyndrickx L, Vanham G, Pozzetto B, Bourlet T. Visualization of X4- and R5-Tropic HIV-1 Viruses Expressing Fluorescent Proteins in Human Endometrial Cells: Application to Tropism Study. PLoS One. 2017;12(1):e0169453. IF=2.8
  3. Paul  S, Williet  N, Di Bernado  T, Berger  AE, Boschetti  G, Filippi  J & al. Soluble Mucosal Addressin Cell Adhesion Molecule 1 and Retinoic Acid are Potential Tools for Therapeutic Drug Monitoring in Patients with Inflammatory Bowel Disease Treated with Vedolizumab: A Proof of Concept Study.  J Crohns Colitis.  2018; in press.
  4. Girard A, Jelicic K, Van Ryk D, Rochereau N, Cicala C, Arthos J, Noailly B, Genin C, Verrier B, Laurant S, Razanajaoana-Doll D, Pin JJ, Paul S. Neutralizing and targeting properties of a new set of α4β7-specific antibodies are influenced by their isotype. J Acquir Immune Defic Syndr. 2017;75:118-127. IF=4.98
  5. Chabert A, Damien P, Verhoeven PO, Grattard F, Berthelot P, Zeni F & al. Acetylsalicylic acid differentially limits the activation and expression of cell death markers in human platelets exposed to Staphylococcus aureus strains. Sci Rep. 2017;7:5610.
  6. Depincé AE, Dussert E, Vergnon-Miszczycha D, Keita A, Pillet S, Botelho-Nevers E, Frésard A, Gagneux-Brunon A, Lucht FR, Roblin X, Pozzetto B, Paul S, Bourlet T. The Genotyping Resistance Profile of the Pol Gene Detected in Blood of Newly Diagnosed HIV-Positive Men Is Durably Archived in the Gut Whatever the Time of Initiation of cART.  Intervirology. 2016;59: 256-261.
  7. Gagneux-Brunon A, Nasri D, Terrasse R, Sauné K, Gagnieu MC, Frésard A, Delezay O, Izopet J, Pozzetto B, Lucht F, Bourlet T. Persistent But Not Replicating HIV-1 Cell-Associated DNA in Semen of Long-Term ART Experienced Men. Curr HIV Res. 2016;14(4):316-23. IF=1.46
  8. Depincé-Berger AE, Vergnon-Miszczycha D, Girard A, Frésard A, Botelho-Nevers E, Lambert C, Del Tedesco E, Genin C, Pozzetto B, Lucht F, Roblin X, Bourlet T & Paul S. Major influence of CD4 count at the initiation of cART on viral and immunological reservoir constitution in HIV-1 infected patients. Retrovirology. 2016;13(1):44. IF=3.42
  9. Girard A, Vergnon-Miszczycha D, Depincé-Berger AE, Roblin X, Lucht F, Lambert C, Rochereau N, Bourlet T, Genin C, Paul S. A High Rate of β7+ Gut-Homing Lymphocytes in HIV-Infected Immunological Nonresponders is Associated With Poor CD4 T-Cell Recovery During Suppressive HAART. J Acquir Immune Defic Syndr. 2016; 1;72(3):259-65. IF=4.98
  10. Paul S, Dillon MBC, Arlehamn CSL, Huang H, Davis MM, McKinney DM & al. A population response analysis approach to assign class II HLA-epitope restrictions. J Immunol. 2015; 194:6164-6176.
  11. Paul S, Boschetti G, Rinaudo-Gaujous M, Moreau A, Del Tedesco E, Bonneau J & al. Association of Anti-glycan Antibodies and Inflammatory Bowel Disease Course. J Crohns Colitis. 2015;9:445-51.
  12. Rochereau N, Pavot V, Verrier B, Ensinas A, Genin C, Corthésy B, Paul S. Secretory IgA as a vaccine carrier for delivery of HIV antigen to M cells. Eur J Immunol. 2015;45(3):773-9. IF=4.9
  13. Pillet S, Jarlot C, Courault M, Del Tedesco E, Chardon R, Saint-Sardos P, Presles E, Phelip JM, Berthelot P, Pozzetto B, Roblin X. Infliximab Does Not Worsen Outcomes During Flare-ups Associated with Cytomegalovirus Infection in Patients with Ulcerative Colitis. Inflamm Bowel Dis. 2015;21(7):1580-6.
  14. Rinaudo-Gaujous M, Roblin X, Marotte H, Paul S. The antibody response against human and chimeric anti-TNF therapeutic antibodies primarily targets the TNF binding region. Ann Rheum Dis. 2015;74: e40.
  15. De Saint Jean A, Lucht F, Bourlet T, Delézay O. Transforming growth factor beta 1 up-regulates CD169 (sialoadhesin) expression on monocyte-derived dendritic cells: role in HIV sexual transmission. AIDS.  2014;28:2375-80.
  16. Lourenço AG, Komesu MC, Machado AA, Quintana SM, Bourlet T, Pozzetto B, Delezay O. Semen lactoferrin promotes CCL20 production by epithelial cells: Involvement in HIV transmission. World J Virol. 2014; 3:11-7.
  17. Lourenço  AG, Komesu MC, Machado AA, Bourlet T, Pozzetto B, Delézay O. Potential contribution of saliva to the sexual transmission of HIV through the secretion of CCL20 by genital epithelial cells. J Med Virol. 2014;86:58-63

 

 

Review Articles

Team member as leader

 

  1. Maillard N, Mariat C. The Oxford Classification for immunoglobulin A nephropathy: a common language blurred by dissonant voices. Nephrol Dial Transplant  2019 in press. IF=4.6   
  2. Ward MG, Sparrow MP, Roblin X. Therapeutic drug monitoring of vedolizumab in inflammatory bowel disease: current data and future directions. Therap Adv Gastroenterol. 2018; 11:1756284818772786. eCollection 2018. IF=3.17
  3. Labetoulle R, Paul S, Roblin X. Filgotinib for the treatment of Crohn's disease. Expert Opin Investig Drugs. 2018; 27(3):295-300. IF=3.88
  4. Flamant M, Roblin X. Inflammatory bowel disease: towards a personalized medicine. Therap Adv Gastroenterol. 2018; 10;11:1756283X17745029. eCollection 2018. IF=4.17
  5. Morgene MF, Botelho-Nevers E, Grattard F, Pillet S, Berthelot P, Pozzetto B, Verhoeven PO. Staphylococcus aureus colonization and non-influenza respiratory viruses: Interactions and synergism mechanisms. Virulence. 2018;9(1):1354-1363. IF=3.95
  6. Hamzeh-Cognasse H, Berthelot P, Tardy B, Pozzetto B, Bourlet T, Laradi S & al. Platelet toll-like receptors are crucial sensors of infectious danger moieties. Platelets. 2018;29:533-540 IF=2.36
  7. Gagneux-Brunon A, Lucht F, Launay O, Berthelot P, Botelho-Nevers E. Vaccines for healthcare-associated infections: present, future, and expectations. Expert Rev Vaccines. 2018;17(5):421-433. IF=4.27.
  8. Gagneux-Brunon A, Rochereau N, Botelho-Nevers E, Lucht F, Pozzetto B, Paul S, Bourlet T. Humoral responses against HIV in male genital tract: role in sexual transmission and perspectives for preventive strategies. AIDS. 2017;31:1055-1064. IF=5
  9. Chazot R, Botelho-Nevers E, Frésard A, Maillard N, Mariat C, Lucht F, Gagneux-Brunon A. Diagnostic challenges of kidney diseases in HIV-infected patients. Expert Rev Anti Infect Ther. 2017;15(10):903-915. IF=3.14
  10. Gayet R, Rochereau N, Corthésy B, Paul S. How to rethink new potent vaccine strategies against Salmonella thanks to recent advances? Microbiology and Molecular Biology Review 2017; 14;81(3). IF=16.4
  11. Flamant M, Rigaill J, Paul S, Roblin X. Advances in the Development of Janus Kinase Inhibitors in Inflammatory Bowel Disease: Future Prospects. Drugs. 2017;77(10):1057-1068. IF=4.69
  12. Flamant M, Paul S, Roblin X. Golimumab for the treatment of ulcerative colitis. Expert Opin Biol Ther. 2017;17(7):879-886. IF=3.68
  13. Harzallah I, Rigaill J, Williet N, Paul S, Roblin X. Golimumab pharmacokinetics in ulcerative colitis: a literature review. Therap Adv Gastroenterol. 2017;10(1):89-100. IF=4.17
  14. Gagnaire J, Verhoeven PO, Grattard F, Rigaill J, Lucht F, Pozzetto B, Berthelot P, Botelho-Nevers E. Epidemiology and clinical relevance of Staphylococcus aureus intestinal carriage: a systematic review and meta-analysis. Expert Rev Anti Infect Ther. 2017;15(8):767-785. IF=3.14
  15. Roblin X, Williet N, Peyrin-Biroulet L. Thiopurine Metabolism in the Era of Combotherapy. Inflamm Bowel Dis. 2016;22(6):1496-501. IF=4.52
  16. Pillet S, Pozzetto B, Roblin X. Cytomegalovirus and ulcerative colitis: Place of antiviral therapy. World J Gastroenterol. 2016;22(6):2030-45. IF=3.37
  17. Gutjahr A, Tiraby G, Perouzel E, Verrier B, Paul S. Triggering Intracellular Receptors for Vaccine Adjuvantation. Trends Immunol. 2016;37(9):573-587. IF=13.29
  18. Gutjahr A, Phelip C, Coolen AL, Monge C, Boisgard AS, Paul  S & al. Biodegradable Polymeric Nanoparticles-Based Vaccine Adjuvants for Lymph Nodes Targeting. Vaccines (Basel). 2016;4  IF=3.24
  19. Weber E, Gagneux-Brunon A, Jacomo V, Rousselon T, Lucht F, Botelho-Nevers  E. Tenosynovitis: a rare presentation of tuberculosis better known by hand surgeons than infectious diseases specialists.  Infection. 2015;43:261-6. IF=2.62
  20. Cognasse F, Nguyen KA, Damien P, McNicol A, Pozzetto B, Hamzeh-Cognasse H & al. The Inflammatory Role of Platelets via Their TLRs and Siglec Receptors. Front Immunol. 2015; 6:83 IF=5.5
  21. Williet N, Paul S, Peyrin-Biroulet L, Roblin X. Pharmacokinetics of Infliximab and Reduction of Treatment for Inflammatory Bowel Diseases. Dig Dis Sci. 2016;61:990-5. IF=2.88
  22. Maillard N, Wyatt RJ, Julian BA, Kiryluk K, Gharavi A, Fremeaux-Bacchi V, Novak J. Current Understanding of the Role of Complement in IgA Nephropathy. J Am Soc Nephrol. 2015; 26(7):1503-12. IF=8.66
  23. Gagneux-Brunon A, Grattard F, Morel J, Suy F, Fuzellier JF, Verhoeven P & al. Mycoplasma hominis a Rare but True Cause of Infective Endocarditis. J Clin Microbiol. 2015; 53:3068-71. IF=4.05
  24. Bonneau J, Dumestre-Perard C, Rinaudo-Gaujous M, Genin C, Sparrow M, Roblin X, Paul S. Systematic review: new serological markers (anti-glycan, anti-GP2, anti-GM-CSF Ab) in the prediction of IBD patient outcomes. Autoimmun Rev. 2015;14(3):231-45. IF=8.96
  25. De Saint Jean A, Bourlet T, Delézay O. Pivotal Role of the Genital Epithelial Cells in HIV-1 Transmission. Curr HIV Res. 2015;13:479-89. IF=1.60
  26. Roblin X, Rinaudo M, Sparrow MP, Moreau A, Phelip JM, Genin C, Lamarque D, Paul S. Pharmacokinetics in IBD: ready for prime time? Curr Drug Targets. 2014;15(11):1049-55. IF=3.11
  27. Paul S, Moreau AC, Del Tedesco E, Rinaudo M, Phelip JM, Genin C, Peyrin-Biroulet L, Roblin X. Pharmacokinetics of adalimumab in inflammatory bowel diseases: a systematic review and meta-analysis. Inflamm Bowel Dis. 2014;20(7):1288-95. IF=4.52
  28. Pillet S, Roblin X, Cornillon J, Mariat C, Pozzetto B. Quantification of cytomegalovirus viral load. Expert Rev Anti Infect Ther. 2014;12(2):193-210. IF=3.46
  29. Verhoeven PO, Gagnaire J, Botelho-Nevers E, Grattard F, Carricajo A, Lucht F & al. Detection and clinical relevance of Staphylococcus aureus nasal carriage: an update. Expert Rev Anti Infect Ther. 2014;12:75-89. IF=3.14
  30. Pavot V, Rochereau N, Lawrence P, Girard  MP, Genin C, Verrier B, Paul S. Recent progress in HIV vaccines inducing mucosal immune responses. AIDS.2014;28:1701-18. IF=6
  31. Gagneux-Brunon A, Suy F, Pouvaret A, Pillet S, Tarantino E, Bouchet D & al. Acute acalculous cholecystitis a rare complication of Epstein-Barr virus primary infection: report of two cases and review. J Clin Virol. 2014;61:173-5. IF=3.02